• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Can-Fite Biopharma Ltd ADR (NY: CANF )

    4.400 -0.100 (-2.22%)
    Streaming Delayed Price Updated: 10:38 AM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 96,264
    Open 4.550
    Bid (Size) 4.350 (2)
    Ask (Size) 4.460 (1)
    Prev. Close 4.500
    Today's Range 4.360 - 4.690
    52wk Range 1.810 - 4.560
    Shares Outstanding 515,746,293
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
    From Can-Fite BioPharma Ltd.
    Via Business Wire

    Performance

    YTD
    +112.56%
    +112.56%
    1 Month
    +61.47%
    +61.47%
    3 Month
    +122.22%
    +122.22%
    6 Month
    +124.49%
    +124.49%
    1 Year
    +45.21%
    +45.21%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Can Fite Biofarma: Q4 Earnings Insights
    Via Benzinga
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Can-Fite Reports 2023 Financial Results and Clinical Update
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.